Revolutionising Oncology: Taipei Medical University and Oncoshot Forge a Path to Personalised Cancer Care
Taipei Medical University (TMU) stands as a distinguished institution for medical education and research in Taiwan. This forward-thinking system aims to amplify inbound trial opportunities and establish a global presence through a platform for exchanging real-time insights, thereby assisting hospitals and research institutions in maintaining their leadership in clinical research through collaborative industry ventures.
Is there a Clinical Trial for You? Introducing Recommend Tx.
Especially for patients with advanced or aggressive cancers, time is of the essence. Without access to advanced tools or algorithms, patients may find it challenging to locate trials tailored to their unique medical profile. Recognising this, Oncoshot has developed Recommend Tx, a ground-breaking Large Language Model (LLM) AI feature that interprets free-text cancer information to match cancer patients with high-value clinical trials.
Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan
Japan presently ranks as the third-largest pharmaceutical market worldwide. This strategic partnership aims to synergise Buzzreach and Oncoshot’s complementary strengths to enhance various aspects of clinical trials, including feasibility assessments, participant screening, and enrolment throughout Japan.
Invest Victoria Case Study: Oncoshot Scales Clinical Data in Melbourne
'Singaporean healthtech leader, Oncoshot, has based its Australian headquarters in Melbourne, to leverage the city's world-leading cancer capability and hospital networks, making it the ideal location to support the company’s international growth.'
Celebrating Cancer Survivors Day: A Patient's Inspiring Journey Towards Genomic Data Digitalisation in Cancer Care
Susan's story shed light on the urgent need to constantly match clinical and genomic cancer data to the evolving landscape of clinical trials.
Kolhapur Cancer Centre and Oncoshot Open Cancer Clinical Trial Access to Rural India
While the incidence of cancer in rural India is nearly half of that of urban India, the mortality rates are double due to the lack of adequate healthcare facilities, awareness about cancer and its risk factors, and limited access to cancer screening and treatment services.
Oncoshot and Gleneagles Global Hospitals Bring Cancer Clinical Trial Patient Matching to South India
Many cancer patients in India remain largely unaware of clinical trials. However, the recent infrastructural advancements in the local private hospitals make India an ideal platform for conducting clinical trials.
BIACH and Oncoshot India Partnership Brings Cancer Clinical Trials to the Less Privileged
Earlier last year, Oncoshot India signed an MOU with the Basavatarakam Indo-American Cancer Hospital (BIACH) in May. The hospital’s objective is to serve the community and is run on a not-for-profit basis. It is a national-level healthcare institution specialising in cancer capabilities in research and education.
Harnessing Existing Genomic Data to Benefit Cancer Patients and Clinical Trials
Our goal is to positively impact five million cancer patients globally, but we have recognised that we are also building a platform to support the development of tens, ideally hundreds, of drugs in the long term.
Oncoshot Wins 2022 Digital Capability Award by the Australian Chamber of Commerce Singapore
The awards celebrate the achievements of businesses and individuals who are leaders in their fields.
Oncoshot and Novotech Partner to Offer Cancer Data Insights
As a provider of clinical development services across all clinical trial phases and therapeutic areas, Novotech will leverage the Oncoshot platform to understand matching populations across key clinical trial markets in the APAC region.
First SEA Genomic Data Digitisation Collaboration Formed to Improve Cancer Clinical Trial Access
Oncoshot has just announced one of its biggest collaborations to date with Icon Cancer Centre in Singapore, alongside Roche. Together the partners plan to facilitate more comprehensive genomic profiling data to increase access to more trial options for cancer patients.
Oncoshot Works With Novartis To Reform Clinical Trials Management
Oncoshot has established a strategic partnership with Novartis to leverage its Project EISE platform which has the potential to enable more patients to access clinical trials in Singapore. EISE (pronounced as ‘easy’), an acronym for ‘Enhanced Clinical Trial Initiation, Screening and Enrolment,’ is a nationwide collaborative effort that connects cancer patients through an integrated, state-of-the-art care system.
The Australian Clinical Trials Ecosystem and The Challenges Oncoshot Aims to Address
Check out this insightful video interview of our CEO and Co-Founder Huren Sivaraj about our recent partnership with Omico, the Australian Genomic Medicine Centre. Here he discusses the priorities in the Australian clinical trial ecosystem and the current challenges Oncoshot aims to address.
Oncoshot Enters Collaboration Agreement With Omico (Australian Genomic Cancer Medicine Centre)
Oncoshot has just entered into a collaboration agreement with Omico, the Australian Genomic Cancer Medicine Centre. The respective parties were represented at the event yesterday by Dr Huren Sivaraj, CEO and co-founder of Oncoshot, and Prof David Thomas, CEO of Omico and head of Genomic Cancer Medicine at the Garvan Institute.
Oncoshot Receives Funding To Expand Cancer Data Sharing Capabilities For Hospitals and Industry
Oncoshot today announced a pre-series A funding round led by MassMutual Ventures (MMV). Other investors for this stage come from a suite of healthtech veterans that include Milltrust International and health industry angel investors.
Oncoshot Enters Into MOU With Singapore Clinical Research Institute
Oncoshot has signed a memorandum of understanding with the Singapore Clinical Research Institute (SCRI), the national coordinating body for clinical trials under the newly launched Consortium for Clinical Research and Innovation Singapore (CRIS). The signing event held last Wednesday was witnessed by guest-of-honour Minister for Health Mr Ong Ye Kung.
Milltrust Ventures to Invest in First-In-Class Health Tech Platform Oncoshot
SINGAPORE, March 22, 2022 /PRNewswire/ – Oncoshot has announced it will be welcoming Dr Bernard Ng, Chief Scientific Officer of Milltrust Ventures, to its advisory board this month. This comes as a first step as the specialist investment organization finances the fast-growing health tech company founded in Singapore.
Oncoshot launches InSite Feasibility and partners AstraZeneca to streamline recruitment process for cancer clinical trials
AstraZeneca will tap into Oncoshot’s data analytic capabilities of InSite Feasibility to introduce more relevant and innovative cancer clinical trials to Singapore.
Dr Raghav Sundar: The precision oncology wave in Singapore is coming
Public and private sectors in Singapore are harnessing genomic data through technologies such as Artificial Intelligence to advance the field of precision oncology.